opdivo
Bristol Myers Squibb receives positive CHMP opinion for Opdivo treatment
April 4, 2025Research and Development CHMP, Oncology, bristol myers squibb, immunotherapy, lung cancer, opdivo
Bristol Myers Squibb (BMS) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for …
NICE shoots down Bristol-Myers Squibb immunotherapy Opdivo for post-surgery skin cancer
November 5, 2020Sales and Marketing BMS, Cancer, NHS, NICE, opdivo
NICE has rejected the routine use of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) on the NHS in England and Wales for …
Opdivo/Yervoy combo secures FDA approval for malignant pleural mesothelioma
October 6, 2020Manufacturing and Production, Research and Development Bristol-Myers Squibb, Yervoy, bristol myers squibb, opdivo
Bristol Myers Squibb’s therapy regimen of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) has secured FDA approval for the first-line …
Opdivo scores NICE recommendation in two non-small cell lung cancer indications
September 17, 2020Sales and Marketing NICE, lung cancer, opdivo
NICE has announced its recommendation of Bristol-Myers Squibb’s blockbuster immunotherapy drug Opdivo (nivolumab) for the treatment of two non-small cell …
Bristol-Myers Squibb demonstrates potential for long-term survival in kidney cancer patients treated with Opdivo plus Yervoy
February 20, 2020Business Services Cancer, Cancers, Yervoy, opdivo, renacl cell carcinoma, renal cancer
Bristol-Myers Squibb has announced updated results from trialing Opdivo (nivolumab) plus Yervoy (ipilimumab) versus sunitinib in patients with previously untreated …
Opdivo + cabiralizumab combo falls flat in advanced pancreatic cancer
February 19, 2020Research and Development Bristol-Myers Squibb, Five Prime Therapeutics, Pancreatic cancer, cabiralizumab, opdivo, pharma
Five Prime Therapeutics and Bristol-Myers Squibb have confirmed that their randomised Phase 2 trial investigating the efficacy of the former’s …
BMS pulls Opdivo+Yervoy combo in EU for advanced non-small cell lung cancer
February 3, 2020Sales and Marketing BMS, Cancer, Europe, Yervoy, lung cancer, opdivo
Bristol-Myers Squibb has confirmed it has withdrawn its application with the European Commission for its combination of Opdivo (nivolumab) and …
Keytruda overtakes Opdivo to lead sales in global immune checkpoint inhibitor market, report reveals
November 19, 2019Manufacturing and Production, Sales and Marketing Bristol-Myers Squibb, MSD, keytruda, opdivo, pharma
MSD’s Keytruda (pembrolizumab) overtook Bristol-Myers Squibb’s (BMS) blockbuster drug Opdivo (nivolumab) in total sales in the third quarter of 2019 …
BMS’ Opdivo+Yervoy+Chemo combo shows superior overall survival in first-line lung cancer
October 23, 2019Research and Development Bristol-Myers Squibb, Cancer, NSCLC, Yervoy, lung cancer, opdivo, pharma
Bristol Myers Squibb has lifted the curtain on new Phase 3 data for its blockbuster immunotherapy Opdivo (nivolumab), showing that …
BMS’ Opdivo bests chemotherapy in oesophageal squamous cell carcinoma
October 2, 2019Research and Development Bristol-Myers Squibb, Cancer, ESMO 2019, opdivo, pharma
Bristol-Myers Squibb took the opportunity at the European Society for Medical Oncology (ESMO) 2019 Annual Congress to present new Phase …
EMA’s CHMP recommends new dosing schedule for Opdivo in melanoma
September 25, 2019Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, CHMP, EMA, melanoma, opdivo, pharma
Bristol-Myers Squibb has revealed that its blockbuster immunotherapy drug Opdivo (nivolumab) has secured recommendation from the EMA’s Committee for Medicinal …
BMS’ Opdivo falls short at Phase 3 in glioblastoma multiforme
September 5, 2019Research and Development BMS, glioblastoma multiforme, opdivo, pharma
Bristol-Myers Squibb has revealed that its blockbuster immunotherapy Opdivo (nivolumab) fell short of its primary Phase 3 endpoint in the …
BMS’ blockbuster Opdivo flies high and falls short in non-small cell lung cancer
July 25, 2019Research and Development Bristol-Myers Squibb, NSCLC, immuntherapy, lung cancer, opdivo, pharma
Bristol-Myers Squibb has pulled back the veil on new data from two analyses of its blockbuster immunotherapy Opdivo (nivolumab) in …
BMS Opdivo/Yervoy recommended for untreated kidney cancer via Cancer Drugs Fund
April 5, 2019Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, Kidney cancer, NICE, UK, Yervoy, opdivo
NICE has revealed it is recommending that Bristol-Myers Squibb’s Opdivo (nivolumab), in combination with Yervoy (ipilimumab), be made available to …
Bristol-Myers Squibb withdraws lung cancer combo therapy marketing application
January 25, 2019Medical Communications BMS, Merck, Yervoy, ctla4, lung cancer, opdivo
Bristol-Myers Squibb has been forced to withdraw a marketing application for its combination of Opdivo and Yervoy for lung cancer. …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
